- The PCWP Add-On, FDA-cleared in July 2026, is now commercially available in the U.S., giving providers a noninvasive indicator of elevated pulmonary capillary wedge pressure
- New CDS tool pairs CorVista test results with published clinical guidelines, to supply next-step guidance for providers leveraging the test’s coronary artery disease, pulmonary hypertension and elevated pulmonary capillary wedge pressure results.
- Together, they make the CorVista System a frontline tool for guideline-driven care across conditions that account for up to 75% of people with symptomatic cardiovascular disease
CorVista Health today announced the launch of CorVista Clinical Decision Support (CDS) and the U.S. commercial availability of the CorVista® System Pulmonary Capillary Wedge Pressure (PCWP) Add-On. The two milestones mark the next step for the CorVista platform: moving beyond noninvasive test results to clear, guideline-recommended next steps for patients.
A key barrier to bringing advanced cardiopulmonary diagnostics into primary care is clinical fit. Physicians need to not only understand diagnostic results, but more importantly, how to evaluate them in the appropriate clinical context. Pairing CorVista results with established clinical guidelines enables this context, providing an estimated post-test probability for coronary artery disease (CAD), and guideline-based recommendations for the combination of CAD, pulmonary hypertension (PH) and elevated PCWP results.
From pre-test to post-test probability
CorVista CDS works in three steps:
- Pre-test probability. The physician enters the patient's age, sex, symptoms and cardiovascular risk factors to establish a pre-test probability from established clinical guidelines.
- CorVista results. The CorVista System results from its FDA-cleared CAD, PH and PCWP algorithms are applied using its statistical performance from validated clinical studies.
- Guideline-driven recommendations. CDS provides the health care provider (HCP) the estimated CAD post-test probability, plus the guideline recommendations that match the patient’s combination of results.
CDS provides yet another tool to help guide each decision and reinforces guideline recommendations with every patient, all while empowering the HCP as the decision-maker.
PCWP now available to U.S. providers
The PCWP Add-On, which received FDA clearance in July 2026, uses an AI-based algorithm to indicate the likelihood of elevated PCWP from the same 3.5-minute resting acquisition used for CorVista’s CAD and PH algorithms. Elevated PCWP is a key indicator of possible heart failure, including both heart failure with reduced ejection fraction (HFrEF) and heart failure with preserved ejection fraction (HFpEF), which combined affect an estimated 7.7 million U.S. adults. HFpEF is estimated to account for more than half of heart failure cases, carries a worse prognosis and remains underdiagnosed. Interpreted together, the PH and PCWP results give providers additional context on whether elevated pulmonary pressure may be related to left-sided heart disease, such as heart failure, or to other causes, such as pulmonary arterial hypertension (PAH) — an important distinction, as these conditions are evaluated and managed differently. The CorVista CAD, PH and PCWP tests together provide the physician with a clearer view of the patient’s cardiovascular health at the point of care. Coupling the CorVista results with CDS, allows for guideline-based recommendations to guide the patient to the appropriate next steps in their diagnostic and therapeutic journey.
“Providing more data is not necessarily enough; a diagnostic result only creates value when it delivers actionable insights leading to the right next step in care,” said Adrian Lam, President and Chief Executive Officer, CorVista Health. “With clinical decision support and PCWP now in physicians’ hands, CorVista is helping health care teams provide accessible, guideline-driven care and act with confidence across CAD, pulmonary hypertension and heart failure.”
Charles R. Bridges, M.D., Sc.D., Executive Vice President and Chief Scientific Officer, added, “By combining established guideline-grounded recommendations with CorVista’s validated diagnostic performance, we give physicians a patient-specific probability of disease and a clear path forward. Adding PCWP means more patients with suspected heart failure, and particularly HFpEF, can be identified earlier and routed to the appropriate care pathway.”
About the CorVista® System
Developed and manufactured by Analytics For Life and commercialized in the U.S. by CorVista Health, the CorVista® System is a point-of-care digital health platform that analyzes sensor-acquired physiological signals to indicate the likelihood of specified cardiovascular conditions, including significant coronary artery disease, elevated mean pulmonary arterial pressure, and elevated pulmonary capillary wedge pressure. Results are presented for interpretation by healthcare providers in conjunction with clinical judgment and the patient's signs, symptoms, and clinical history as an aid in diagnosis. The system received FDA clearance for coronary artery disease in September 2023, pulmonary hypertension in April 2024, and elevated PCWP in July 2026. In 2022, the CorVista System's pulmonary hypertension indication received FDA Breakthrough Device Designation. CorVista Clinical Decision Support is a separate application, independent of the FDA-cleared CorVista System.
Category III CPT code 1104T is effective as of Oct. 1, 2026, and supports reporting for the use of the CorVista System in the assessment of potential CAD, PH, and elevated PCWP using augmentative algorithmic analysis of orthogonal voltage gradient and photoplethysmography signals.
About CorVista Health
CorVista Health is on a mission to transform cardiovascular care with diagnostics that shorten the path from symptoms to diagnosis, empowering earlier treatment and better patient outcomes. For more information, visit www.corvista.com.
Sources
- 2024 ESC Guidelines for the management of chronic coronary syndromes, published August 30, 2024. This supplies the risk-factor–weighted clinical likelihood lookup.
- 2021 AHA/ACC/ASE/CHEST/SAEM/SCCT/SCMR Guideline for the Evaluation and Diagnosis of Chest Pain, published October 28, 2021.
- 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure, published April 1, 2022.
- 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension, published August 26, 2022.
View source version on businesswire.com: https://www.businesswire.com/news/home/20261118570037/en/
Contacts
Media Contact
Grant Smith
VP, Marketing & Communications
media@corvista.com
